Targeted therapy for colorectal cancer: mapping the way
作者： Simone Mocellin , Mario Lise , Donato Nitti
DOI: 10.1016/J.MOLMED.2005.05.002
关键词:
摘要: In spite of the significant advances in conventional therapeutic approaches to colorectal cancer (CRC), most patients ultimately die their disease. Dissecting molecular mechanisms underlying CRC progression will not only accelerate development novel cancer-selective drugs but also enable regimen be personalized according features individual and tumors. Here, we report on insights into biology that are paving way therapies summarize results from recent clinical trials demonstrating agents targeting tumor-specific derangements can significantly improve efficacy chemotherapy. Only a broader implementation these concepts provide with best chance cure.
core.ac.uk
elsevier.com
sci-hub.se 参考文章(76)
Harvey R. Herschman, Noninvasive imaging of reporter gene expression in living subjects. Advances in Cancer Research. ,vol. 92, pp. 29- 80 ,(2004) , 10.1016/S0065-230X(04)92003-9
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Guy Chung-Faye, Syed Hussain, Peter Searle, Philip I. Murray, David Anderson, Joanna Baddeley, David Ferry, Daniel Palmer, Joanna Clark, Peter A. Harris, David J. Kerr, Mandy Downes, Leonard Seymour, Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clinical Cancer Research. ,vol. 7, pp. 2662- 2668 ,(2001)
David Kirn, Robert L. Martuza, James Zwiebel, Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nature Medicine. ,vol. 7, pp. 781- 787 ,(2001) , 10.1038/89901
Jules E. Harris, Louise Ryan, Herbert C. Hoover, Robert K. Stuart, Martin M. Oken, Al B. Benson, Edward Mansour, Daniel G. Haller, Judith Manola, Michael G. Hanna, Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283 Journal of Clinical Oncology. ,vol. 18, pp. 148- 148 ,(2000) , 10.1200/JCO.2000.18.1.148
Simone Mocellin, Carlo R. Rossi, Pierluigi Pilati, Donato Nitti, Francesco M. Marincola, Quantitative real-time PCR: a powerful ally in cancer research Trends in Molecular Medicine. ,vol. 9, pp. 189- 195 ,(2003) , 10.1016/S1471-4914(03)00047-9
John M Mariadason, Diego Arango, Leonard H Augenlicht, Customizing chemotherapy for colon cancer: the potential of gene expression profiling Drug Resistance Updates. ,vol. 7, pp. 209- 218 ,(2004) , 10.1016/J.DRUP.2004.05.001
J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J. P. Fandl, T. Daly, S. J. Wiegand, G. D. Yancopoulos, J. S. Rudge, VEGF-Trap: A VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 11393- 11398 ,(2002) , 10.1073/PNAS.172398299
Daniel B. Longley, D. Paul Harkin, Patrick G. Johnston, 5-Fluorouracil: mechanisms of action and clinical strategies Nature Reviews Cancer. ,vol. 3, pp. 330- 338 ,(2003) , 10.1038/NRC1074
Eileen D. Adamson, Anthony R. Rees, Epidermal growth factor receptors. Molecular and Cellular Biochemistry. ,vol. 34, pp. 129- 152 ,(1981) , 10.1007/BF02359619